Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 128   

Articles published

NVO 43.81 -0.59 (-1.33%)
price chart
Novo Nordisk And Eli Lilly Battling To Win GLP-1 Drug Market
Novo Nordisk A/S (ADR) (NVO) is currently leading the GLP-1 agonist space with its injectable drug Victoza, which was launched in 2009.
Related articles »  
Novo Nordisk's (NVO) Diabetes Drug Victoza Receives Positive Review By CHMP
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Friday that its key drug Victoza has received positive reviews from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for the treatment of type 2 diabetes ...
Related articles »  
Sanofi And Novo Nordisk's Basal-Insulin Battle Continues
Sanofi SA (ADR) (SNY) and Novo Nordisk A/S (ADR) (NVO) are the two main players in the ongoing race for developing effective basal insulin therapies for the treatment of diabetes.
Related articles »  
Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race
Novo Nordisk A/S (ADR) (NVO) announced yesterday, that its insulin therapy Tresiba, which was in late-stage trials, has proved to be safe and effective for the treatment of type 1 diabetes in children and young adults.
Related articles »  
Novo Nordisk A/S (ADR) (NVO), Colgate-Palmolive Company (CL), and ...
The pharmaceutical company has a second quarter net profit margin of 32.34% and reported a 44.20% return on average assets and a 79.87% return on average equity.
Novo Nordisk A/S (ADR) (NVO): A Company Solving The Global Diabetes Crisis ...
Novo Nordisk A/S (NYSE: NVO) is the undisputed global leader in the diabetes market. The company's impressive product portfolio is home to five of the world's 10 best-selling diabetes medications.
Related articles »  
Trend Analysis Report: Novo Nordisk A/S (ADR) (NYSE:NVO), Tata Motors ...
Manhattan, NY- 28 November, 2014 - (Techsonian) - Novo Nordisk A/S (ADR) (NYSE:NVO) holds in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark.
Related articles »  
McDonald's Corporation (MCD), Novo Nordisk A/S (ADR) (NVO), Colgate ...
Novo Nordisk A/S (ADR) (NYSE:NVO) also kept its spot in Mr. Simons' list. The $189 billion market cap healthcare company witnessed a 5% boost in the fund's exposure between April and June.
Is Novo Nordisk A/S (ADR) (NVO) Going to Burn These Hedge Funds?
Out of the hedge funds we follow, Renaissance Technologies, managed by Jim Simons, holds the largest position in Novo Nordisk A/S (ADR) (NYSE:NVO). Renaissance Technologies has a $433.1 million position in the stock, comprising 1.1% of its 13F ...
Related articles »  
Novo Nordisk A/S: Stock split information
The trading unit of the Novo Nordisk B shares listed on the stock exchange in Copenhagen will be changed from DKK 1 to DKK 0.20.
Related articles »